Syndax sees Revuforj U.S. peak net revenue in excess of $2B as Q4 axatilimab readouts approach (NASDAQ:SNDX)
· seekingalpha.com
Syndax (SNDX) Q2 2026 earnings call recap: Revuforj/Niktimvo sales, $2B+ peak outlook, Q4 catalysts, and cash runway.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...